+

WO2002062369A3 - Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer - Google Patents

Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer Download PDF

Info

Publication number
WO2002062369A3
WO2002062369A3 PCT/US2002/003201 US0203201W WO02062369A3 WO 2002062369 A3 WO2002062369 A3 WO 2002062369A3 US 0203201 W US0203201 W US 0203201W WO 02062369 A3 WO02062369 A3 WO 02062369A3
Authority
WO
WIPO (PCT)
Prior art keywords
uroguanylin
inhibition
cyclooxygenase
inhibitor
intestinal cancer
Prior art date
Application number
PCT/US2002/003201
Other languages
French (fr)
Other versions
WO2002062369A2 (en
Inventor
Jaime L Masferrer
Original Assignee
Pharmacia Corp
Jaime L Masferrer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp, Jaime L Masferrer filed Critical Pharmacia Corp
Priority to EP02702137A priority Critical patent/EP1365753A2/en
Priority to JP2002562375A priority patent/JP2004521123A/en
Priority to CA002435835A priority patent/CA2435835A1/en
Priority to AU2002235520A priority patent/AU2002235520A1/en
Priority to US10/467,145 priority patent/US20040121961A1/en
Publication of WO2002062369A2 publication Critical patent/WO2002062369A2/en
Publication of WO2002062369A3 publication Critical patent/WO2002062369A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed is a method of retarding the development of polyps and prevention, inhibition and treatment of cancer in the intestine of a subject by administration of a composition comprising a peptide with the active domain of uroguanylin or any agonist peptide or compound binding to the guanylate cyclase receptor GC-C in the intestine in combination with a naturally occurring, derived from a naturally occurring, or a chemically synthesized cycloogenase-2 inhibitor, preferably a selective cyclooxygenase-2 inhibitor.
PCT/US2002/003201 2001-02-02 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer WO2002062369A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02702137A EP1365753A2 (en) 2001-02-02 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
JP2002562375A JP2004521123A (en) 2001-02-02 2002-02-04 Combination of uroguanylin and cyclooxygenase-2 inhibitors for intestinal cancer inhibition
CA002435835A CA2435835A1 (en) 2001-02-02 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
AU2002235520A AU2002235520A1 (en) 2001-02-02 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US10/467,145 US20040121961A1 (en) 2002-02-04 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26595501P 2001-02-02 2001-02-02
US60/265,955 2001-02-02

Publications (2)

Publication Number Publication Date
WO2002062369A2 WO2002062369A2 (en) 2002-08-15
WO2002062369A3 true WO2002062369A3 (en) 2003-08-28

Family

ID=23012573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003201 WO2002062369A2 (en) 2001-02-02 2002-02-04 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer

Country Status (5)

Country Link
EP (1) EP1365753A2 (en)
JP (1) JP2004521123A (en)
AU (1) AU2002235520A1 (en)
CA (1) CA2435835A1 (en)
WO (1) WO2002062369A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330312T5 (en) * 2001-03-29 2014-01-31 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SI2246360T1 (en) * 2003-01-28 2012-10-30 Ironwood Pharmaceuticals Inc Compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
WO2005016244A2 (en) 2003-06-13 2005-02-24 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2559319T3 (en) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Guanylate cliclas agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2559840T3 (en) 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
KR20170016522A (en) 2008-08-15 2017-02-13 아이언우드 파마슈티컬스, 인코포레이티드 Linaclotide-containing formulations for oral administration
EP2341898A2 (en) * 2008-09-04 2011-07-13 Ironwood Pharmaceuticals, Inc. Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration
CA2745694C (en) 2008-12-03 2018-03-27 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
MX386452B (en) 2010-02-17 2025-03-18 Ironwood Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF GASTROINTESTINAL DISORDERS.
HUE046922T2 (en) 2010-08-11 2020-03-30 Ironwood Pharmaceuticals Inc Stable formulations of linaclotide
CA2810243C (en) 2010-09-15 2021-04-20 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6312592B2 (en) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド Treatment of digestive disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047890A1 (en) * 1997-04-21 1998-10-29 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
WO2000023433A1 (en) * 1998-04-17 2000-04-27 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047890A1 (en) * 1997-04-21 1998-10-29 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
WO2000023433A1 (en) * 1998-04-17 2000-04-27 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FORTE L R: "GUANYLIN REGULATORY PEPTIDES: STRUCTURES, BIOLOGICAL ACTIVITIES MEDIATED BY CYCLIC GMP AND PATHOBIOLOGY", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 81, no. 1 - 3, 31 May 1999 (1999-05-31), pages 25 - 39, XP000979549, ISSN: 0167-0115 *
KAWAMORI T ET AL: "CHEMOPREVENTIVE ACTIVITY OF CELECOXIB, A SPECIFIC CYCLOOXYGENASE-2 INHIBITOR, AGAINST COLON CARCINOGENESIS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, 1 February 1998 (1998-02-01), pages 409 - 412, XP001145866, ISSN: 0008-5472 *
SHAILUBHAI ET AL: "UROGUANYLIN TREATMENT SUPPRESSES POLYP FORMATION IN THE APCMIN/+ MOUSE AND INDUCES APOPTOSIS IN HUMAN COLON ADENOCARCINOMA CELLS VIA CYCLIC GMP", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 18, 2000, pages 5151 - 5157, XP002159386, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
AU2002235520A1 (en) 2002-08-19
JP2004521123A (en) 2004-07-15
WO2002062369A2 (en) 2002-08-15
EP1365753A2 (en) 2003-12-03
CA2435835A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
WO2002062369A3 (en) Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
WO2001068092A3 (en) Glycogen phosphorylase inhibitor
WO2002046129A3 (en) Inhibitors of histone deacetylase
WO2002047712A3 (en) Peptide yy and peptide yy agonists for treatment of metabolic disorders
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
WO2002042295A3 (en) Peptides as met-ap2 inhibitors
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
EP1734041A3 (en) Platelet ADP receptor inhibitors
WO2005032555A3 (en) Pharmaceutical combinations of hydrocodone and naltrexone
EP2261236A3 (en) Composition for proteasome inhibition
HUP0200623A2 (en) 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors and pharmaceutical compositions containing them
NO996352D0 (en) <Kappa> antagonist compounds, pharmaceutical compositions and procedures for the prevention and treatment of pruritus
HUP0101158A3 (en) Use of glycogen phosphorylase inhibitors for the preparation of pharmaceutical compositions for the prophylactic treatment of type 2 diabetes mellitus
HK1044528A1 (en) Monoamine reuptake inhibitors for treatment of cnsdisorders.
ZA200207290B (en) Pharmaceutical compositions of glycogen phosphorylase inhibitors.
AU2003277440A1 (en) Compositions of cyclooxygenase-2 selective inhibitors and nmda receptor antagonists for the treatment or prevention of neuropathic pain
NO20033985L (en) Topical patch preparation containing a delayed type of hypersensitivity inducing agent and methods for using it.
CA2409771A1 (en) Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
IL166621A0 (en) Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
WO2002070524A3 (en) N-but-3-enyl norbuprenorphine and its use as analgesic
WO2002016312A3 (en) NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY
ZA200403690B (en) Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI).
NO2010004I1 (en) 0.02 mg of ethinylostradiol (as betadexclathrate) and 3mg drospirenone
AU2002223633A1 (en) Use of stimulators of soluble guanylate cyclase for treating osteoporosis
BG105197A (en) Polymorph form of a medicament

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002702137

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2435835

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002562375

Country of ref document: JP

Ref document number: 10467145

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002702137

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002702137

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载